- theory and concepts
- decision theory
- decision psychology
- probability/bayes
- priority setting/ethics
- evidence synthesis
- microsimulation
- dynamic simulation
- approaches and applications
- decision analysis
- risk analysis
- benefit-cost analysis
- cost-effectiveness analysis
- technology assessment
- operations research
- chronic disease/risk
- mental health
- global
- north america
Resources Repository
-
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | Mental Health | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Microsimulation | Cost-Effectiveness Analysis | North America | Global | Chronic Disease/Risk | Test Performance | State-Transition | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine -
ArticlePublication 2021Global Costs, Health Benefits, & Economic Benefits of Scaling Up Treatment and Imaging Modalities for Survival of 11 Cancers
This analysis estimated the costs and lifetime health and economic benefits of scaling up imaging …
This analysis estimated the costs and lifetime health and economic benefits of scaling up imaging and treatment modality packages on cancer survival in 200 countries/territories for patients diagnosed with one of 11 cancers (oesophagus, stomach, colon, rectum, anus, liver, pancreas, lung, breast, cervix uteri, and prostate). Using a microsimulation model of global cancer survival, the paper evaluated the costs and health and economic benefits of scaling up packages of treatment (chemotherapy, surgery, radiotherapy, and targeted…
Priority Setting/Ethics | Microsimulation | Benefit-Cost Analysis | Global | Chronic Disease/Risk | Health Outcomes | Health Systems -
ArticlePublication 2017Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease …
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease (CVD) risk factor reduction policies, specifically highlighting new insights into the differential impacts of well-established CVD prevention interventions. Tobacco taxation, salt reduction, and primary prevention of CVD in high-risk individuals remain widely regarded as best buys in global noncommunicable disease policy, and the ECEAs confirm the findings of previous CEAs, namely, that these interventions will likely result in large health…
Evidence Synthesis | Priority Setting/Ethics | Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | Health/Medicine -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
Microsimulation | Cost-Effectiveness Analysis | Decision Analysis | North America | Chronic Disease/Risk | Infectious Diseases | Health/Medicine -
ArticlePublication 2015A Conceptual Model for Breast, Cervical, and Colorectal Cancer Screening
General frameworks of the cancer screening process are available, but none directly compare the process …
General frameworks of the cancer screening process are available, but none directly compare the process in detail across different organ sites. This limits the ability of medical and public health professionals to develop and evaluate coordinated screening programs that apply resources and population management strategies available for one cancer site to other sites. This paper presents a conceptual model that incorporates a single screening episode for breast, cervical, and colorectal cancers into a unified framework based…
Evidence Synthesis | Microsimulation | Cost-Effectiveness Analysis | North America | Chronic Disease/Risk | Preferences/Values | Health Outcomes | Test Performance | Health Systems | Clinical Care | Health/Medicine | Science/Technology -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Priority Setting/Ethics | Technology Assessment | Cost-Effectiveness Analysis | North America | Chronic Disease/Risk | Infectious Diseases | Child/Nutrition | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
ReviewPublication 2023Economic & Humanistic Burden of Osteoarthritis: Systematic Review of Large Sample Studies
This study systematically reviewed and updated the economic and humanistic burden of osteoarthritis (OA) reported …
This study systematically reviewed and updated the economic and humanistic burden of osteoarthritis (OA) reported by large sample studies since 2016. Medline (via Ovid) and Embase were searched using an updated strategy based on a previous review. Studies with a sample size ≥1000 that measured direct or indirect costs or health-related quality of life (HRQL) of OA were included. Pairs of reviewers independently screened studies, and an arbitrator resolved discrepancies. The Kappa value for agreement…
Evidence Synthesis | Cost-Effectiveness Analysis | Global | Chronic Disease/Risk | Preferences/Values | Health/Medicine -
ArticlePublication 2023New Type 2 Diabetes Microsimulation Model to Estimate Long-Term Health Outcomes, Costs, Cost-Effectiveness
This study presents a microsimulation model designed to estimate the health effects, costs, and cost-effectiveness …
This study presents a microsimulation model designed to estimate the health effects, costs, and cost-effectiveness of interventions for type 2 diabetes in the United States. Unlike existing models that rely on UK data, this model incorporates newly derived risk equations based on US studies, enhancing its applicability to the US context. The model features a highly modular architecture allowing for easy addition of new modules and interventions, facilitating policy decision-making. Internal validation showed good performance,…
Microsimulation | Cost-Effectiveness Analysis | North America | Chronic Disease/Risk | Health/Medicine